These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28654980)

  • 1. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration.
    Cheng CW; Wu TX; Shang HC; Li YP; Altman DG; Moher D; Bian ZX;
    Ann Intern Med; 2017 Jul; 167(2):112-121. PubMed ID: 28654980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration (Traditional Chinese Version).
    Cheng CW; Wu TX; Shang HC; Li YP; Altman DG; Moher D; Bian ZX;
    Ann Intern Med; 2017 Jul; 167(2):W7-W20. PubMed ID: 28654988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting quality and risk of bias of randomized controlled trials of Chinese herbal medicine for multiple sclerosis.
    Wu JY; Yang JL; Hu JL; Xu S; Zhang XJ; Qian SY; Chen ML; Ali MA; Zhang J; Zha Z; Zheng GQ
    Front Immunol; 2024; 15():1429895. PubMed ID: 39229262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improving the quality of reporting Chinese herbal medicine trials: an elaborated checklist].
    Fei YT; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2008 Mar; 6(3):233-8. PubMed ID: 18334139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the quality of randomized controlled trials in Chinese herbal medicine, part IV: applying a revised CONSORT checklist to measure reporting quality.
    Bian ZX; Moher D; Dagenais S; Li YP; Wu TX; Liu L; Miao JX; Song L; Zhang HM
    Zhong Xi Yi Jie He Xue Bao; 2006 May; 4(3):233-42. PubMed ID: 16696907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reporting quality of randomized controlled trials in Chinese herbal medicine (CHM) formulas for diabetes based on the consort statement and its extension for CHM formulas.
    Liu Y; Hu C; Zhou K; Zhang Y; Kang J; Wen Y; Yuan R; Li J; Zhao Q; Zhang L; Yang X
    Front Pharmacol; 2024; 15():1288479. PubMed ID: 38318135
    [No Abstract]   [Full Text] [Related]  

  • 7. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020).
    Zhang X; Tan R; Lam WC; Yao L; Wang X; Cheng CW; Liu F; Chan JC; Aixinjueluo Q; Lau CT; Chen Y; Yang K; Wu T; Lyu A; Bian Z
    Am J Chin Med; 2020; 48(6):1279-1313. PubMed ID: 32907365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement.
    Gagnier JJ; Boon H; Rochon P; Moher D; Barnes J; Bombardier C;
    Ann Intern Med; 2006 Mar; 144(5):364-7. PubMed ID: 16520478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.
    Boutron I; Moher D; Altman DG; Schulz KF; Ravaud P;
    Ann Intern Med; 2008 Feb; 148(4):295-309. PubMed ID: 18283207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.
    Moher D; Hopewell S; Schulz KF; Montori V; Gøtzsche PC; Devereaux PJ; Elbourne D; Egger M; Altman DG;
    Int J Surg; 2012; 10(1):28-55. PubMed ID: 22036893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials.
    Moher D; Hopewell S; Schulz KF; Montori V; Gøtzsche PC; Devereaux PJ; Elbourne D; Egger M; Altman DG;
    J Clin Epidemiol; 2010 Aug; 63(8):e1-37. PubMed ID: 20346624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Herbal CONSORT statement and standardization of reporting traditional Chinese drug trials].
    Fei YT; Liu JP
    Zhongguo Zhong Yao Za Zhi; 2008 Jan; 33(1):89-94. PubMed ID: 18338628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO Trial Registration Data Set (TRDS) extension for traditional Chinese medicine 2020: recommendations, explanation, and elaboration.
    Zhang X; Lan L; Chan JCP; Zhong LLD; Cheng CW; Lam WC; Tian R; Zhao C; Wu TX; Shang HC; Lyu AP; Bian ZX
    BMC Med Res Methodol; 2020 Jul; 20(1):192. PubMed ID: 32680474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
    Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
    Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of compliance of CONSORT-CHM formula 2017 in randomized controlled trials of Chinese herbal medicine formulas: protocol of a five-year review.
    Wang J; Cheng CW; Jiao Y; Shi D; Wang Y; Li H; Wang N; Wang X; Li Y; Liang F; Luo S; Han F; Li J; Wang P; Lyu A; Bian Z; Zhang X
    Front Pharmacol; 2024; 15():1287262. PubMed ID: 38464724
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of the Consolidated Standards of Reporting Trials (CONSORT) checklist on reporting of randomized clinical trials in traditional Chinese medicine.
    Liu XT; Zhang X; Wen S; Peng L; Hong Q; Kang D
    J Evid Based Med; 2015 Nov; 8(4):192-208. PubMed ID: 26334556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting quality of Cochrane systematic reviews with Chinese herbal medicines.
    Zhang X; Aixinjueluo QY; Li SY; Song LL; Lau CT; Tan R; Bian ZX
    Syst Rev; 2019 Dec; 8(1):302. PubMed ID: 31796121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments.
    Boutron I; Moher D; Altman DG; Schulz KF; Ravaud P;
    Ann Intern Med; 2008 Feb; 148(4):W60-6. PubMed ID: 18283201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement.
    MacPherson H; Altman DG; Hammerschlag R; Li Y; Wu T; White A; Moher D;
    Acupunct Med; 2010 Jun; 28(2):83-93. PubMed ID: 20615861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology.
    Bian ZX; Li YP; Moher D; Dagenais S; Liu L; Wu TX; Miao JX; Kwan AK; Song L
    Zhong Xi Yi Jie He Xue Bao; 2006 Mar; 4(2):120-9. PubMed ID: 16529686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.